INNOVADERM CRO IS NOW INDERO.
READ THE ANNOUNCEMENT
Talk to us

European Academy of Dermatology and Venereology (EADV) Congress

September 30-October 3, 2026

Vienna, Austria

Discover how Indero can support your next dermatology trial. Schedule your meeting for the 2026 EADV Congress.

Presentations by:

Dr. Robert Bissonnette, MD, FRCPC
Founder and Executive Chairman, Indero

Wednesday, September 30th ‱ 17:00 - 17:15 CEST
Efficacy and safety of lunsekimig in moderate-to-severe atopic dermatitis: Results from the phase 2b VELVET trial
Part of: Late Breaking News

Saturday, October 3rd ‱ 14:15 - 15:45 CEST
From Protocol to Patient: Mastering the Logistics of Clinical Trial Setup
Part of: International Eczema Council (IEC): The Relevance of Clinical Trials and Real-World Data

Dr. Robert Bissonnette's e-Poster Presentations

Psoriasis – Part I

  • Reduction of Skin CD8 TRMs in Icotrokinra-Treated Participants With Moderate-to-Severe Plaque Psoriasis: Phase 3 ICONIC-LEAD Results Through Week 52

Psoriasis – Part III

  • Comparison of In-Person, Virtual, and Artificial Intelligence-Augmented Assessments of Psoriasis Disease Severity
  • Durability of Systemic and Skin Pharmacodynamic Responses With Icotrokinra in Moderate-to-Severe Plaque Psoriasis: Phase 3 ICONIC-LEAD Week 52 Results

Atopic Dermatitis/Eczema – Part III

  • Abrocitinib Modulates Multi-Axis Immune Activation in Moderate-to-Severe AD patients who Failed Dupilumab

Biologics, Immunotherapy, Targeted Therapy

  • SPECTREM: High-Impact Site Skin Clearance and Itch Improvement Through Week 48 With Guselkumab in Participants With Low Body Surface Area, Moderate Psoriasis
  • Safety, Pharmacokinetics, and Pharmacodynamics of ATTO-1310, a Novel ANTI-IL31 ATTOBODY-FC Fusion Protein, in Healthy Adults

Schedule Your Meeting Now

Fields marked with * are required.

Talk to us

Jeff Smith

Chef de la direction
Linkedin

Jeff Smith, Chef de la direction d’Indero Recherches, apporte prĂšs de 30 ans d’expĂ©rience dans l’industrie pharmaceutique et CRO, s’Ă©tant distinguĂ© par son leadership exceptionnel, sa vision stratĂ©gique et son innovation. L’expertise de Jeff couvre des opĂ©rations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matiĂšre de crĂ©ation de valeur, de gestion des partenaires et d’opĂ©rations CRO ont toujours contribuĂ© au succĂšs dans ses fonctions prĂ©cĂ©dentes. Sous la direction de Jeff, Indero continue d’étendre ses capacitĂ©s, faisant progresser les connaissances mĂ©dicales et les nouvelles thĂ©rapies en dermatologie et en rhumatologie.